NEPC Session Descriptions

PROGRAM | HOTEL | SPONSOR OR EXHIBIT | CE INFO | REGISTER

The Connecticut Pharmacists Association is accredited by The Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. 



SESSION 1
APhA’s The Pharmacist & Patient-Centered Diabetes Care Certificate Program
Lisa DeGennaro, PharmD, BCPS, CDE, Assistant Professor of Pharmacy, University of Saint Joseph School of Pharmacy


SESSION 2
APhA’s Delivering Medication Therapy Management Services Certificate Program
Sheila Seed, PharmD, MPH, RPh, CTH, Professor & Chair of Pharmacy Practice, MCPHS University
Jason Cross, PharmD, BCPS, BCACP, Associate Professor of Pharmacy Practice, MCPHS University


SESSION 4
Prescription Digital Therapeutics: A Novel Modality to be Integrated into Standard of Care Pharmacotherapy for Patients (1 contact hour; 0.1 CEU)
Dr. Yuri Maricich, CMO & Head of Clinical Development, Pear Therapeutics

1. Create an overview on Prescription Digital Therapeutics – a new modality of therapeutics.
2. Describe the unmet need for developing prescription digital therapeutics for the treatment of substance use disorders (SUDs).
3. Review the clinical evidence for digital therapeutics as safe and effective options to be added to pharmacotherapy for SUDs.
4. Recognize the role of the pharmacist in the healthcare team in helping patients combat SUDs using digital therapeutics as well as investigational PDTs currently in development.
5. Summarize Pipeline PDTs In Development and Future of Combination of software and pharmacologic treatments.


SESSION 5
Pharmacists on the Front Line as Immunizer and Educator: Addressing the Inconvenient Truth of Vaccine Refusal (1 contact hour; 0.1 CEU)
Tom Buckley, MPH, RPh
Associate Clinical Professor of Pharmacy Practice
Department of Pharmacy Practice, UCONN School of Pharmacy


1. Describe the current status of the 2019 measles outbreak
2. Identify the sources of a measles outbreak that was previously eradicated
3. Demonstrate the pharmacist’s role in vaccine education
4. Apply effective strategies to address vaccine myths and misconceptions


SESSION 6
Pain Management in the Face of Opioid Stewardship (1 contact hour; 0.1 CEU)
Trinh Bui, PharmD, Clinical Pharmacist, Smilow Cancer Hospital

1. Review guidelines for responsible pain management with opioids
2. Discuss the role of adjunctive medications for pain control
3. Identify novel therapeutic agents that are being developed as non-opioid analgesics and describe how they might be added to current practice
4. Develop pain management regimens using guideline recommendations for case studies


SESSION 7
You are Pharmacy’s Best Advocate: Taking Grassroots Action to the Capitol (Law CE) (1 contact hour; 0.1 CEU)
Jean Cronin
Partner, Hughes & Cronin Public Strategies

1. Describe how a bill becomes a law and how pharmacists can monitor the status of proposed bills during the Legislative Session.
2. Identify the tools and resources that pharmacists can use to develop their authentic grassroots voice at the local, state and national level.
3. Describe the strategies pharmacists utilize to prepare for a one-on-one talk with their legislators or a personalized outreach to legislators.
4. Recall how pharmacists can identify their elected officials and their contact information.
5. Explain how pharmacists can use local media to educate legislators and the public at large about the impact of certain policy proposals on the pharmacy practice as well as patient care.


SESSION 8
Keynote Address: Early Access to Investigational Medicines–New Hope, Hype or Confusion? (1 contact hour; 0.1 CEU)
Anne B. Cropp, PharmD, BCAP
Chief Scientific Officer, Early Access Care

1. Describe the FDA pathways for pre-approval access to investigational medicines, the Federal Right to Try law, and the circumstances under which either path is an option.
2. Explain patient eligibility for early access to manage patient inquiries for early access to investigational medicines.
3. Identify the ethical challenges of early access–equipoise, patient, physician, pharmacist and industry risk.
4. Define considerations on impact to clinical development programs for new investigational therapies.


SESSION 9
Dirofilaria, CHF, and NSAIDs for Lions, Tigers, and Bears… Oh My! (1 contact hour, 0.1 CEU)
Carolyn Arnish, PharmD, RPh
Pharmacy Manager, Dedham Pharmacy & Medical Supply


1. Highlight the training a pharmacist can pursue to become a veterinary pharmacist and review the history of veterinary pharmacists in the United States
2. Describe the life cycle of Dirofilaria immitis (heartworms) as well as treatment paradigms used for prevention and eradication of infection in dogs (Specific to New England Region)
3. Review the pathophysiology of congestive heart failure in dogs and cats and compare/contrast approved human vs veterinary therapeutic agents currently utilized in practice
4. Delineate differences in human-approved vs. veterinary-approved anti-inflammatory agents for veterinary patients and the benefits and dosing of each option


SESSION 1O
Pharmacy Law Update: 2019 Legislative Session (Law CE) (1 contact hour; 01. CEU)
Rod Marriott, PharmD
Director, Drug Control Division, CT Dept of Consumer Protection


1. Describe the new laws pertaining to interchangeable biological products.
2. Explain the changes to the telehealth laws.
3. Explain the new limitations on self and family prescribing.
4. Identify common inspection findings.
5. Recall refusal to fill/moral and ethics issues in the news.


SESSION 11
Student Poster Session


SESSION 12
Pathophysiology and the Effect of Treatment in Type 1 Diabetes (0.83 contact hours; 0.08 CEU)
Lisa Cohen, PharmD
Associate Professor, Univ of Rhode Island School of Pharmacy


1. Compare and contrast pathophysiology and presentation of type 1 and type 2 diabetes
2. Review the data from the DCCT and EDIC trials and identify the role pharmacists can help with the complications and improve the control of type 1 diabetes
3. Inspect the data from the T1D Exchange and describe opportunities for pharmacists to become members of the T1D care team


SESSION 13
Diabetes-Related Technology: More Than Just Apps with the Advent of the Artificial Pancreas (AP) (0.83 contact hours; 0.08 CEU)
Jennifer Sherr, MD, PhD
Assistant Professor
Yale School of Medicine


1. Discuss the role of insulin pumps and continuous glucose monitoring systems in the care for those with T1D
2. Describe the Artificial Pancreas technology, including systems that are commercially available, currently in development and the DIY approach.
3. Review how and where a pharmacist can impact patient care and outcomes for patients with T1D.


SESSION 14
T1D Care in 2019: We’ve Come a Long Way (0.83 contact hours; 0.08 CEU)
Andrew Vilcinskas
UCONN School of Pharmacy


1. Review the pharmacokinetics of insulins (human and analog) and compare them to the advancements with modern basal and ultra-rapid acting analog insulins
2. Describe clinical cases of patients being initiated on insulin for newly diagnosed T1D to highlight insulin dosing strategies and treatment goals highlighting the role the pharmacist can play on this care team
3. Describe the clinical development of adjunctive therapies for T1D to include pramlintide, metformin, DPP4 inhibitors, GLP1 agonists as well as SGLT2-SGLT1/2-inhibitors and the role they may play in the future management of T1D along with insulin


SESSION 15
Panel Discussion: Advancing the Role of Pharmacists on the Type I Diabetes Care Team (0.51 contact hours; 0.051 CEU)
Lisa Cohen, Jennifer Sherr and Andrew Vilcinskas

1. Discuss the opportunities and challenges for pharmacists to enhance patient outcomes through the development of diabetes-related technology with the spectrum of available insulins.
2. Discuss the impact of obesity on patients with T1D who become insulin resistant and develop characteristics of T2D and how adjunctive medications might provide added benefit.
3. Discuss the role that pharmacists can play on the type 1 diabetes care team for newly diagnosed patients.


SESSION 16
Cannabis: A Poison Control Perspective (0.83 contact hours; 0.08 CEU)
Dayne Laskey, PharmD, DABAT
Assistant Professor, Univ. St. Joseph School of Pharmacy


1. Describe the pharmacology of cannabinoids.
2. Identify cannabinoid use trends in the U.S.
3. Explain clinical manifestations of cannabinoid use in adults in children


SESSION 17
Clearing the Smoke on Cannabis Use Disorder: Prevalence, Neurobiology, and Treatment (0.83 contact hours; 0.08 CEU)
Dr. Alyssa Peckham, PharmD, BCPP, Clinical Assistant Professor of Pharmacy, Northeastern University

1. Describe the prevalence of cannabis use and the DSM-V diagnostic criteria for Cannabis Use Disorder (CUD).
2. Review the neurobiology of addiction in relation to cannabis.
3. Discuss the approaches to pharmacotherapy for CUD that have been studied as well as provide an overview of current on-going clinical trials for CUD pharmacotherapy


SESSION 18
Pharmacy or Dispensary: Cannabinoid Therapy Options (0.83 contact hours; 0.08 CEU)
Al Domeika, PharmD
Dispensary Manager, Prime Wellness of CT

1. Discuss the history of cannabis as a medicine.
2. Explain how federal policies changed the classification and views of cannabis as a viable medicine.
3. Review FDA-approved cannabinoid-based medicines available by prescription.
4. Identify different types of cannabis medicines available in dispensary facilities.
5. Discuss CBD products that can be purchased over-the-counter.


SESSION 19
Panel Discussion: Advancing the Role of Pharmacists As Cannabis Educators (0.51 contact hours; 0.051 CEU)
Dayne Laskey, Dr. Alyssa Peckham, and Al Domeika

1. Recall the pharmacology of cannabinoids and the history of cannabis in its role as a viable medicine.
2. Discuss the role that pharmacists can play in educating patients about CBD products and other cannabis medicines available in dispensaries.
3. Explain how pharmacists can best communicate with patients about the signs/symptoms of Cannabis Use Disorder (CUD) integrating information regarding therapies that could be considered for CUD.


SESSION 20
Basic Principles and Concepts of Pharmacogenomics (0.83 contact hours; 0.08 CEU)
Maria Summa, PharmD, BCPS
Chair, Associate Professor of Pharmacy
Univ of St. Joseph School of Pharmacy


1. Define basic pharmacogenomic nomenclature and how genetic variation contributes to inter-individual variability in drug response.
2. Describe how pharmacogenomic information is being used to improve patient care.
3. Identify key resources that curate knowledge about the impact of genetic variation on drug response.
4. Communicate recommendations and explanations about pharmacogenomic tests and associated results to patients and other members of the healthcare team.


SESSION 21
Applications of Pharmacogenomics and Precisions Medicine in Oncology Care (0.83 contact hours; 0.08 CEU)
Nick Forcello, PharmD, BCPS, BCOP
Smilow Cancer Center


1. Illustrate established applications of genomics in oncology practice.
2. Explain newer applications of genomics being applied to both new and old antineoplastic agents and supportive care.
3. Discuss potential future applications of precision medicine in oncology patients.


SESSION 22
NEX-GEN Care: Optimizing Psychopharmacotherapy With Pharmacogenomic Applications (0.83 contact hours; 0.08 CEU)
Cristofer Price, PharmD
Clinical Pharmacy Program Manager, Mental Health
Providence Veterans Affairs Medical Center


1. Review common metabolic pathways involved in psychopharmacotherapeutics and identify clinical challenges associated with genetic variability in these pathways 
2. Discuss controversy surrounding the role for genomic data in psychopharmacotherapy.
3. Review available online resources for information regarding pharmacogenomics.
4. Review patient cases where pharmacogenomic testing could be used to improve pharmacotherapy decisions with patients living with depression, bipolar disorder, and/or schizophrenia.


SESSION 23
Panel Discussion: Putting Pharmacogenomics Principles Into Practice (0.51 contact hours; 0.051 CEU)
Maria Summa, Nick Forcello and Cristofer Price

1. Recall the definition of pharmacogenomics and describe its role in enhancing the treatment of oncology patients and patients with major depression, bipolar depression and schizophrenia.
2. Discuss how pharmacists can best communicate recommendations/explanations about pharmacogenomics tests and associated results to patients and the health care team.
3. Demonstrate an understanding of potential future applications of pharmacogenomics in patient care